Boehringer’s new zongertinib data demonstrates durable and clinically meaningful results in patients with HER2 (ERBB2)-mutant advanced NSCLC
Hand-out
Press Releases
April 28, 2025

Boehringer’s new zongertinib data demonstrates durable and clinically meaningful results in patients with HER2 (ERBB2)-mutant advanced NSCLC

New data from the Phase Ib Beamion LUNG-1 trial were presented at AACR and simultaneously published in The New England Journal of MedicineData presented included an objective response rate (ORR)

bradford

The Bradford Era

More by this Author
Local & Social